StreetInsider.com News Articles

Form 4 Ginkgo Bioworks Holdings For: Oct 16 Filed by: Canton Barry

Wed, 21 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261021/27216432.html

Form 4 Ginkgo Bioworks Holdings For: Oct 16 Filed by: Coen Steven P.

Wed, 21 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261021/27216437.html

Form 4 Ginkgo Bioworks Holdings For: Oct 16 Filed by: Kelly Jason R

Wed, 21 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261021/27216411.html

Form 4 Ginkgo Bioworks Holdings For: Oct 16 Filed by: Shetty Reshma P.

Wed, 21 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261021/27216421.html

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Mon, 19 Oct 2026 15:58:00 -0400

si-local-file:///var/storage/secattach/20261019/27203689.html

Form 144 Ginkgo Bioworks Holdings Filed by: Canton Barry

Mon, 19 Oct 2026 15:47:00 -0400

si-local-file:///var/storage/secattach/20261019/27203635.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Mon, 19 Oct 2026 15:45:00 -0400

si-local-file:///var/storage/secattach/20261019/27203621.html

Form 144 Ginkgo Bioworks Holdings Filed by: Shetty Reshma P.

Mon, 19 Oct 2026 15:43:00 -0400

si-local-file:///var/storage/secattach/20261019/27203608.html

Form 144 Ginkgo Bioworks Holdings Filed by: Kelly Jason R

Mon, 19 Oct 2026 15:39:00 -0400

si-local-file:///var/storage/secattach/20261019/27203578.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Mon, 19 Oct 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20261019/27202189.html

Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $11 at TD Cowen

Tue, 13 Oct 2026 07:44:31 -0400

TD Cowen analyst Brendan Smith raised the price target on Ginkgo Bioworks Holdings Inc (NYSE: DNA) to $11.00 (from $9.00) while maintaining a Hold rating.

Ginkgo Bioworks to offer lab access to NSF X-Labs researchers

Thu, 08 Oct 2026 16:10:30 -0400

Ginkgo Bioworks (NYSE: DNA) announced it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program, a $1.5 billion, decade-long initiative funding independent research teams pursuing milestone-based science awards.

The announcement was made by Michael Kratsios, Director of the White House Office of Science and Technology Policy, at the Science: A New Golden Age Summit in Washington, D.C.

Under the arrangement, Ginkgo will make cloud lab time available to NSF X-Labs teams, giving researchers remote access to robotic lab infrastructure to design, run, and analyze experiments. Ginkgo will also offer protein testing services, enabling

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program

Thu, 08 Oct 2026 16:10:00 -0400

BOSTON--(BUSINESS WIRE)-- Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C.

NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engineers, and entrepreneurs pursuing breakthrough science through milestone-based awards. Through its contribution, Ginkgo will make cloud lab time on its autonomous lab available to NSF

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program

Thu, 08 Oct 2026 16:10:00 -0400

Ginkgo Bioworks adds Araceli imaging system to its autonomous lab

Thu, 08 Oct 2026 06:02:14 -0400

Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous laboratory in Boston.

The Endeavor can image a 1536-well plate in under four minutes and runs continuously within Nebula's Reconfigurable Automation Cart (RAC) system. Araceli's ClaireRT™ software analyzes each well as images are captured, and can alert operators or pause imaging when results fall outside defined criteria.

Nebula is built on modular RAC units that combine robotic arms, automated sample transport, and unified control software. The system operates around the clock and uses approximately one-third of the space a traditional lab bench

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop

Thu, 08 Oct 2026 06:00:00 -0400

The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research

PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston. The Endeavor, the world's fastest high-content imaging system,

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop

Thu, 08 Oct 2026 06:00:00 -0400

The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research

Form 4 Ginkgo Bioworks Holdings For: Oct 05 Filed by: Coen Steven P.

Wed, 07 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261007/27161901.html

Increasing unusual option volume: INDA GMAB PACB RMD XP DNA UNM LION EXC

Tue, 06 Oct 2026 10:17:20 -0400

Increasing unusual option volume: INDA GMAB PACB RMD XP DNA UNM LION EXC

Increasing unusual call option volume: PACB DNA CWH XP PAGS PUSA NXH

Tue, 06 Oct 2026 05:44:37 -0400

Increasing unusual call option volume: PACB DNA CWH XP PAGS PUSA NXH

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Mon, 05 Oct 2026 14:04:00 -0400

si-local-file:///var/storage/secattach/20261005/27148159.html

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Tue, 29 Sep 2026 08:00:00 -0400

Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris’ federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on their proprietary molecules or train new models using the consortium dataset.

BOSTON--(BUSINESS WIRE)-- Ginkgo Datapoints, an offering of Ginkgo Bioworks (NYSE: DNA), and Apheris GmbH today announced that the Antibody Developability Consortium has kicked off with its founding members. The Consortium is a new industry collaboration designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field’s largest standardized antibody developability dataset.

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Tue, 29 Sep 2026 08:00:00 -0400

Ginkgo Bioworks (DNA) 4K contracts of December 11 calls trade, share price up 15%

Thu, 17 Sep 2026 15:19:51 -0400

Ginkgo Bioworks (NYSE: DNA) 30-day option implied volatility is at 92; compared to its 52-week range of 76 to 183 with a focus on 4K contracts of December 11 calls trading at 60c as share price up 15%.

Ginkgo Bioworks (DNA) 4K contracts of December 11 calls trade, share price up 13.3%

Thu, 17 Sep 2026 15:11:01 -0400